NANT 2015-02: PHASE 1 STUDY OF LORLATINIB (PF-06463922), AN ORAL SMALL MOLECULE INHIBITOR OF ALK/ROS1, FOR PATIENTS WITH ALK-DRIVEN RELAPSED OR REFRACTORY NEUROBLASTOMA
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Margaret Macy, MD
Study ID
Protocol Number: 17-0511
More information available at ClinicalTrials.gov: NCT03107988
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers